Phase III trials

WILMINGTON, Delaware, USA, April 28, 2026 AstraZeneca has announced that its fixed-dose triple-combination therapy Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate) has...

LONDON, UK, April 8, 2026 GSK has announced that China’s National Medical Products Administration (NMPA) has approved Exdensur (depemokimab),...

Montréal, 28 November 2025 In a major development for inflammatory bowel disease (IBD) care, Canada’s Drug Agency (AMC) has...